Naltrexone implant - BioCorRx

Drug Profile

Naltrexone implant - BioCorRx

Alternative Names: BICX 102

Latest Information Update: 22 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BioCorRx
  • Class Analgesics; Cyclopropanes; Drug withdrawal therapies; Irritable bowel syndrome therapies; Morphinans; Small molecules
  • Mechanism of Action Immunomodulators; Opioid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Alcoholism; Opioid abuse

Most Recent Events

  • 15 Nov 2017 BioCorRx enters into confidentiality agreement with the National Institute on Drug Abuse for development of therapies for Opioid abuse
  • 15 Nov 2017 BioCorRx plans pre-IND meeting with the US FDA on 24 January, 2018
  • 01 Jun 2017 Preclinical trials in Alcoholism and Opioid abuse in USA (Implant) before June 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top